康乐卫士

江苏中慧元通生物科技股份有限公司致力于新型人用疫苗和多联多价疫苗的研发、注册申报及产业化生产和销售，瞄准国际水准，替代进口，并实现出口。

宣传思想和红色文化，反映老百姓的呼声，推动社会公平正义，维护国家和民族根本利益。

进口试剂采购网致力于一站式生命科学解决方案，为客户提供进口试剂、细胞培养、抗体、ELISA试剂盒、蛋白&肽、生化试剂、分子类、蛋白纯化等产品!

中国目前最具知名度和影响力的红色爱国网站之一。红歌会网基于一贯的人民立场，高举爱国主义旗帜，唱响红歌，弘扬正气，宣传红色文化，反映老百姓的呼声，推动社会公平正义，维护国家和民族根本利益。

北京同立海源生物专注细胞与基因治疗(CGT)领域GMP级核心原料试剂研发及生产，为CGT用户提供产品与服务的整体解决方案。产品涉及细胞分选磁珠试剂、重组蛋白、无血清培养基、细胞培养试剂盒等。

westvacbiopharmaisfoundedbyacademicianweiyuquanfromwestchinahospitalofsichuanuniversity,togetherwithscientistsfromstatekeylaboratoryofbiotherapy(sklb).itsheadquarterislocatedintheinternationalbio-town,chengdu.theceoofwestvacbiopharmaisprof.weiyuquan,whoistheacademicianofchineseacademyofsciencesaswellasthedirectorofstatekeylaboratoryofbiotherapy.westvaciscommittedtoexploringthelatestbiotherapytechnologiesformajordiseases,includinginfectiousdiseases,malignanttumors,cardiovasculardiseases,andsoon.ithasattachedgreatimportanceintheresearchanddevelopment(r&d)ofcovid-vaccineespeciallyandbuildingacovid-vaccineproductionplatform.statekeylaboratoryofbiotherapy(sklb)wasestablishedbytheministryofsciencesandtechnologyofchinainandbecameoneofthenationalr&dplatformsfornoveldrugsfoundedbytheministriesofsciencesandtechnologyaswellasthatofhealthofchinain.itisalsosupportedbynationalcollaborativeinnovationprogramandhasbecomethenationalcollaborativeinnovationcenterforbiotherapysince.westchinahospitalofsichuanuniversity，foundedin,isthenationalcenterfordiagnosisandtreatmentofsevereandcriticaldiseasesinwesternchina.itisalsotheworld’slargestcomprehensivehospitalcomplexlocatedinonecampusarea.relyingonthemedicalresourcesofstatekeylaboratoryofbiotherapyandwestchinamedicalcenter,westvachasadoptedrecombinantproteinmethodologytodevelopthecovid-vaccine.becauseofthesafetyoftheproteinvaccine,itisalsotheonlycovid-vaccineapprovedfortheuseinchildrenoveryearsoldinchina.thevaccinewasapprovedbythenationalmedicalproductsadministrationforclinicaltrialsonaugust,.phasei/iiclinicaltrialshavebeencompleted,andphaseiiiclinicaltrialsarebeingcarriedoutinnepal,kenya,japanandothercountries.thevaccinetargetsthespikeproteinbindingdomain(s-rbd)ofsars-cov-,producingneutralizingantibodiestoblockcovid-infectionofhumancells.theresultwaspublishedonnature,theworld’sfamousscientificjournalonjulyth,.ithasalsobeenthefirstpaperofcovidvaccinepublishedbynaturesincethepandemicoutbreak.thes-rbdgeneofthecovid-virusisintroducedintotheinsectcells,whichwereusedasafactorytoproducehigh-qualityrecombinantvaccineproteinandthendoesrefinedpurification.suchtechnologyiseasytobemass-producedandbroughttothemarket.westvacbiopharmaiscommittedtobecomingtheworld`sleadingvaccineandimmunotherapyplatform.